Biogen reports $2.5B Q1 revenue, +2% YoY, with non-GAAP EPS of $3.57, up 18%. LEQEMBI’s 78% 18-month persistence rate and a new high-dose SPINRAZA FDA approval signal commercial and pipeline …
Biogen reports $2.5B Q1 revenue, +2% YoY, with non-GAAP EPS of $3.57, up 18%. LEQEMBI’s 78% 18-month persistence rate and a new high-dose SPINRAZA FDA approval signal commercial and pipeline …
Brazil’s MMA-Fiocruz partnership delivers the first Phyllanthus niruri phytotherapeutic for urinary disorders, anchoring a 2035 target of ten native-species drugs through ANVISA’s herbal pathway and SUS formulary integration.
A definitive merger agreement between Sutter Health and Allina Health would create an 88,000-employee nonprofit system with a $2B-plus investment commitment in Minnesota and Wisconsin.
Law 15.385/2026 mandates SUS incorporation of CONITEC-approved oncology drugs while a Fiocruz-MSD partnership delivers 100% domestically produced pembrolizumab, reducing Brazil’s import dependence for a flagship immunotherapy.
Mendoza becomes the first Argentine province to screen newborns for spinal muscular atrophy at birth, enabling pre-symptomatic treatment under a public-private accord with Novartis effective May 24, 2026.
ANS mandates private-plan coverage for olaparib in BRCA-mutant prostate cancer, osimertinib plus chemotherapy in EGFR+ lung cancer, and lebriquizumab in severe atopic dermatitis following a price concession.
Vepdegestrant’s May 1 approval for ESR1-mutant advanced breast cancer marks the first PROTAC-class drug cleared by the FDA, with VERITAC-2 trial data showing a hazard ratio of 0.70 over fulvestrant.
ANVISA’s RDC 1023/2026 formalizes cannabis active pharmaceutical ingredient exports while the 8th Brazilian Pharmacopoeia edition sets new quality benchmarks, positioning Brazil’s industrial health complex for international market entry.
Brazil’s Ministry of Health and ONA have launched the country’s first accreditation manual for digital health, telemedicine, and telehealth services, establishing a formal quality and safety certification pathway for public …
ANVISA has approved serplulimab as the only anti-PD-1 authorized in Brazil for extensive-stage small cell lung cancer, giving Abbott a regulatory head start before larger checkpoint inhibitor rivals.
You must be logged in to post a comment.